Vertex obtains receives European approval for cystic fibrosis oral medicine
The European Commission has approved Vertex Pharmaceuticals' oral medicine Kalydeco (ivacaftor) for people with cystic fibrosis (CF). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 3, 2014 Category: Pharmaceuticals Source Type: news

Cystic fibrosis unit for children opens at University Hospital Galway
New unit includes four examination rooms, treatment room and gym for assessment and physiotherapy, along with support services (Source: The Irish Times - Health)
Source: The Irish Times - Health - July 29, 2014 Category: Consumer Health News Source Type: news

Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped
Title: Cystic Fibrosis Drug Combo May Be Less Effective Than HopedCategory: Health NewsCreated: 7/23/2014 2:36:00 PMLast Editorial Review: 7/24/2014 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - July 24, 2014 Category: Respiratory Medicine Source Type: news

Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped
One medication seems to partly counteract the other, suggests study on human cells (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - July 24, 2014 Category: Respiratory Medicine Authors: webmaster at doctorslounge.com Tags: Pharmacy, Pulmonology, Research, News, Source Type: news

Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped
One medication seems to partly counteract the other, suggests study on human cells (Source: WebMD Health)
Source: WebMD Health - July 23, 2014 Category: Consumer Health News Source Type: news

Unsuspected characteristics of new cystic fibrosis drugs found, offering potential paths to more effective therapies
A large phase 3 clinical trial for cystic fibrosis patients has concluded, showing that a combination of two new cystic fibrosis drugs modestly improved lung function and offered better health outcomes for some patients. Now, scientists have shown that one of these drugs counteracts the intended beneficial molecular effect of the other. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 23, 2014 Category: Science Source Type: news

Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped
One medication seems to partly counteract the other, suggests study on human cells Source: HealthDay Related MedlinePlus Pages: Cystic Fibrosis, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - July 23, 2014 Category: Consumer Health News Source Type: news

Why it's so hard to develop a drug for cystic fibrosis
Two new studies suggest novel therapies can interfere with each other (Source: ScienceNOW)
Source: ScienceNOW - July 23, 2014 Category: Science Source Type: news

Dead man walking: ‘Living with cystic fibrosis - I wasn’t expected to make it past 17’
TIM WOTTON is active, fit, happily married and a proud father - yet it's a miracle that he has reached the age of 43. Here he talks to Express.co.uk about life with the genetic disease cystic fibrosis. (Source: Daily Express - Health)
Source: Daily Express - Health - July 23, 2014 Category: Consumer Health News Source Type: news

UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies
(University of North Carolina Health Care) Last month, the pharmaceutical company Vertex released results from a large phase 3 clinical trial for cystic fibrosis patients, showing that a combination of two new cystic fibrosis drugs modestly improved lung function and offered better health outcomes for some patients. Now, scientists at the University of North Carolina School of Medicine and the University of North Carolina Marsico Lung Institute have shown that one of these drugs counteracts the intended beneficial molecular effect of the other. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 23, 2014 Category: Global & Universal Source Type: news

Costly Drug Is Denied; Medicaid Takes Heat
Vertex Pharmaceuticals' $300,000-a-year cystic-fibrosis drug has sparked a battle in Arkansas, illustrating the dilemma faced by cash-strapped government insurance programs. (Source: WSJ.com: Health)
Source: WSJ.com: Health - July 17, 2014 Category: Pharmaceuticals Tags: PAID Source Type: news

Cystic Fibrosis Market Sales to Grow $5.3 Billion with 28.96% CAGR to...
ReportsnReports.com adds “OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2018 – Event-Driven Update” to its store. The majority of Cystic Fibrosis sales will come from...(PRWeb July 16, 2014)Read the full story at http://www.prweb.com/releases/cystic-fibrosis-market/analysis-forecasts-2018/prweb12022260.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 17, 2014 Category: Pharmaceuticals Source Type: news

Costly Drug Is Denied, Medicaid Takes Heat
Vertex Pharmaceuticals' $300,000-a-year cystic-fibrosis drug has sparked a battle in Arkansas, illustrating the dilemma faced by cash-strapped government insurance programs. (Source: WSJ.com: Health)
Source: WSJ.com: Health - July 17, 2014 Category: Pharmaceuticals Tags: PAID Source Type: news

acapella® choice Helps Cystic Fibrosis Patients
acapella® choice, the stand-alone oscillating Positive Expiratory Pressure (PEP) therapy device, from Smiths Medical, is effective in managing excessive secretion generation and conditions associated with cystic fibrosis. (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 14, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Medical Devices Respiratory Latest News Source Type: news

Fiance of cystic fibrosis patient who died urges people to join donor register
EXCLUSIVE: Josh Nelli, from Kesgrave in Suffolk, is today urging people to sign the Organ Donation Register after his partner of five years Kerry Thorpe died waiting for a double lung transplant at the age of 23. (Source: the Mail online | Health)
Source: the Mail online | Health - July 13, 2014 Category: Consumer Health News Source Type: news

Proud parents urge HSE to fund genetic screening of embryos
Pre-implantation test helped couple who carry Cystic fibrosis gene have healthy baby (Source: The Irish Times - Health)
Source: The Irish Times - Health - July 12, 2014 Category: Consumer Health News Source Type: news

How did a work experience girl make a major cystic fibrosis breakthrough?
Jo Armstead, a 21-year-old medical student, was given a work experience task she thought she could simply 'Google'. Here she explains how instead, it became an 11-month project that led to a significant breakthrough (Source: Telegraph Health)
Source: Telegraph Health - July 8, 2014 Category: Consumer Health News Tags: cystic fibrosis work experience jo armstead research breakthrough student medicine doctor Source Type: news

Birth of first baby screened for Cystic Fibrosis a ‘milestone’
Centre screened embryos for genetic conditions prior to implantation (Source: The Irish Times - Health)
Source: The Irish Times - Health - July 5, 2014 Category: Consumer Health News Source Type: news

PTC Therapeutics begins Phase III trial of Translarna to treat nonsense mutation cystic fibrosis
US-based biopharmaceutical firm PTC Therapeutics has started a global confirmatory Phase III clinical trial of Translarna (ataluren), an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF). (Source: Drug Development Technology)
Source: Drug Development Technology - June 30, 2014 Category: Pharmaceuticals Source Type: news

Vertex Receives European CHMP Positive Opinion for KALYDECO(TM) (ivacaftor) in Eight Non-G551D Gating Mutations
In Europe, approximately 250 people ages 6 and older have one of 8 additional gating mutations KALYDECO is the first medicine to treat the underlying cause of CF in people with non-G551D gating mutations EYSINS, Switzerland--(Healthcare Sales & Marke... Biopharmaceuticals, RegulatoryVertex Pharmaceuticals, KALYDECO, ivacaftor, cystic fibrosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 27, 2014 Category: Pharmaceuticals Source Type: news

Jo Armstead on work experience at Wythenshawe Hospital, makes major cystic fibrosis breakthrough
Newcastle University student Jo Armstead, 21, (pictured) discovered that half of adults who suffer from the rare genetic disorder are infected with a common fungus while working at Wythenshawe Hospital in Manchester. (Source: the Mail online | Health)
Source: the Mail online | Health - June 26, 2014 Category: Consumer Health News Source Type: news

Vertex's Cystic-Fibrosis Treatment Shows Promise
Vertex Pharmaceuticals said it would seek regulatory approval later this year for an experimental cystic-fibrosis drug that helped produce a statistically significant improvement in patients' lung function. (Source: WSJ.com: Health)
Source: WSJ.com: Health - June 25, 2014 Category: Pharmaceuticals Tags: PAID Source Type: news

Should Reporters Have Agreed To The Vertex Embargo?
This morning at 7 a.m., Vertex Pharmaceuticals released big news: adding a new drug, lumacaftor, to its existing cystic fibrosis drug Kalydeco increased by an order of magnitude the number of patients the medicine can help -- although the combo is still not as effective as Kalydeco is in patients who have a particular, rare mutation. I had a story up at 7:05. Adam Feuerstein at TheStreet.com, Andrew Pollack at the New York Times, and Meg Tirrell at CNBC all published their stories at the same time. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 24, 2014 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news

Vertex cystic fibrosis combo succeeds in key late-stage trials
(Reuters) - A combination of Vertex Pharmaceuticals Inc's VRTX.O cystic fibrosis drugs succeeded in improving lung function in a pair of closely watched late-stage trials, likely offering a potential new treatment for thousands more patients with the rare lung disease and sending Vertex shares soaring. (Source: Reuters: Health)
Source: Reuters: Health - June 24, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Vertex Soars 40% On New Cystic Fibrosis Drug Combo Results
Tuesday brought good news for those suffering with cystic fibrosis -- as well as Vertex Pharmaceuticals investors. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 24, 2014 Category: Pharmaceuticals Authors: Brian Solomon Source Type: news

In A Victory For Gene Research, Vertex Drug Combo Clears Lungs Clogged By Cystic Fibrosis
In the war against genetic disease, scientists just gained some important ground. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 24, 2014 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news

Vertex’s 2-Drug Cystic Fibrosis Pill Shows Promise
A combination of its drugs slightly improved lung function of patients with the genetic disease in trials closely watched by Wall Street. (Source: NYT Health)
Source: NYT Health - June 24, 2014 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Cystic Fibrosis Drugs (Pharmaceuticals) Medicine and Health Source Type: news

Aradigm doses first patient in Phase III trial of Pulmaquin
US-based pharmaceutical firm Aradigm has started dosing patients in the ORBIT-4 Phase III clinical trial of its proprietary formulation of inhaled ciprofloxacin (Pulmaquin) to treat non-cystic fibrosis bronchiectasis (non-CF BE). (Source: Drug Development Technology)
Source: Drug Development Technology - June 23, 2014 Category: Pharmaceuticals Source Type: news

New hope for cystic fibrosis... in medication derived from Norwegian seaweed
The active ingredient in the new treatment is a highly purified type of alginate, a carbohydrate found in the walls of sea plants. (Source: the Mail online | Health)
Source: the Mail online | Health - June 14, 2014 Category: Consumer Health News Source Type: news

Cannabis and sunshine may damage sperm quality
ConclusionThis study has found that the shape of sperm is less likely to be normal when samples are provided in summer and if cannabis has been consumed in the previous three months. It has also found that normal-shaped sperm are more likely to be produced after six days of abstinence. It did not find any other links between lifestyle factors and sperm shape.The results of this study alone do not show that lifestyle factors other than cannabis are harmless. Male fertility is not just determined by the shape of the sperm; it is also dependent on the concentration, motility and viability of the sperm, as well as the quality ...
Source: NHS News Feed - June 5, 2014 Category: Consumer Health News Tags: Genetics/stem cells Lifestyle/exercise Cancer Source Type: news

Increased mucins pinned to worsening cystic fibrosis symptoms
The first quantitative evidence that mucins – the protein framework of mucus – are significantly increased in cystic fibrosis patients, and play a major role in failing lung function, has been presented by researchers. The research shows that a three-fold increase of mucins dramatically increases the water-draining power of the mucus layer. This hinders mucus clearance in the CF lung, resulting in infection, inflammation, and ultimately lung failure. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 3, 2014 Category: Science Source Type: news

Cystic fibrosis and diabetes link explained
(Lund University) Many people with cystic fibrosis develop diabetes. The reasons for this have been largely unknown, but now researchers at Lund University in Sweden and Karolinska institutet have identified a molecular mechanism that contributes to the raised diabetes risk. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 2, 2014 Category: Global & Universal Source Type: news

JCI online ahead of print table of contents for June 2, 2014
(Journal of Clinical Investigation) This release contains summaries, links to PDFs, and contact information for the following newsworthy papers published online, June 2, 2014 in the JCI: 'Mucin concentration contributes to a sticky situation in cystic fibrosis,' 'Engineered aptimer targets malignant and tumor-associated T cells,' 'NOTCH inhibits osteoblast formation in inflammatory arthritis via noncanonical NF-κB,' 'Myosin Vb uncoupling from RAB8A and RAB11A elicits microvillus inclusion disease,' 'Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation,' and more. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2014 Category: Cancer & Oncology Source Type: news

A Product For Gaucher Disease And A Plant-Cell For Protein Production – Protalix Biotherapeutics Is On The Rise
Protalix has a unique plant-cell platform for therapeutic protein production and an approved product, Elelyso/Uplyso (taliglucerase alfa), for Gaucher disease. In the company’s pipeline is a chemically modified version of the recombinant alpha-Galactosidase-A protein for Fabry disease (Phase 1/2), an oral glucocerebrosidase (GCD) enzyme replacement therapy for Gaucher disease (Phase 1), an oral anti-TNF (tumor necrosis factor) fusion protein for autoimmune/inflammatory conditions (preclinical), and a human deoxyribonuclease I (DNase I) for cystic fibrosis (preclinical), and other enzyme replacement therapies in early...
Source: Pharmaceutical Online News - May 30, 2014 Category: Pharmaceuticals Source Type: news

Self-confessed former 'bad boy' donates kidney to cystic fibrosis sufferer
Wesley Joyce decided to 'change his life' after the plight of 34-year-old Sally-Anne Grainger, from Worcestershire, who went into renal failure after having to take strong medication following a double lung transplant in 2009. (Source: the Mail online | Health)
Source: the Mail online | Health - May 22, 2014 Category: Consumer Health News Source Type: news

OU research team achieves $4.5 million Defense grant
(University of Oklahoma) A University of Oklahoma research team has been awarded a five-year, $4.5 million grant from the Defense Threat Reduction Agency to address the growing problem of three specific antibiotic resistant pathogens causing devastating infections in hospitals and in persons with cystic fibrosis. The OU research team achieved the only grant of its kind to perform research that potentially will lead to the design of effective antibiotic drugs. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 22, 2014 Category: Biology Source Type: news

Cystic Fibrosis: Once-A-Day Antibiotic Durable
SAN DIEGO (MedPage Today) -- A once-daily inhaled antibiotic appeared to offer long-term benefits in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection, researchers said here. (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - May 21, 2014 Category: Infectious Diseases Source Type: news

Boosting Immune process with IFN-γ helps clear lethal bacteria in cystic fibrosis
Boosting a key immune process called autophagy with interferon gamma -- IFN-³ -- could help clear a lethal bacterial infection in cystic fibrosis, a new study suggests. The work offers new information about immune function in patients with the disease. Cystic fibrosis is caused by a malfunction in the CFTR gene, which is responsible for transporting chloride and water across cell membranes. In people with the disease, cells that line the passageways of the lungs, pancreas and other organs produce unusually thick and sticky mucus that clogs the airways -- creating an ideal environment for pathogens. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 20, 2014 Category: Science Source Type: news

Parents, leave the multivitamins in the bottle
By Carolyn Sax, MD, a primary care physician with the Pediatric Physicians’ Organization at Boston Children’s and practices at Hyde Park Pediatrics in Hyde Park and Milton, Mass. Parents often ask me whether I recommend multivitamins for their children, and in most situations I say no. This takes a lot of people by surprise. Vitamins sound like such a good thing, right? The answer is actually somewhat complicated.  Foods that are naturally rich in vitamins are definitely a good thing, and many scientific studies have shown the benefits of eating a diet rich in nutritious foods like fruits, v...
Source: Thrive, Children's Hospital Boston - May 20, 2014 Category: Pediatrics Authors: Guest Blogger Tags: All posts Carolyn Sax healthy eating healthy eating for kids healthy eating for the whole family vitamins Source Type: news

Boosting Immune process with IFN-γ helps clear lethal bacteria in cystic fibrosis
(Nationwide Children's Hospital) Boosting a key immune process called autophagy with interferon gamma -- IFN-γ -- could help clear a lethal bacterial infection in cystic fibrosis, a new study suggests. The work, published in PLoS One in May, offers new information about immune function in patients with the disease. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 20, 2014 Category: Biology Source Type: news

Solution to helping teens with chronic disease may be at fingertips
(University of California - San Diego) Adolescents with chronic diseases (ACD), such as cystic fibrosis, gastrointestinal disorders (including Crohn's disease) and Type 1 diabetes, often find the transition of managing their health care needs into adulthood to be challenging. A new study by researchers at the University of California, San Diego School of Medicine found the answer to developing independent, self-management skills in ACD could be right at the patient's fingertips. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 19, 2014 Category: Global & Universal Source Type: news

PTC Therapeutics reports positive Phase III trial results of ataluren in nmCF patients
US-based biopharmaceutical firm PTC Therapeutics has reported results of a Phase III double-blind, placebo-controlled trial of ataluren in patients with nonsense mutation cystic fibrosis (nmCF). (Source: Drug Development Technology)
Source: Drug Development Technology - May 18, 2014 Category: Pharmaceuticals Source Type: news

Ataluren Phase 3 trial results in nonsense mutation cystic fibrosis
The results of a Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis have been published, demonstrating positive trends in both the primary endpoint, lung function as measured by relative change in percent predicted FEV1 (forced expiratory volume in one second) and in the secondary outcome measure, rate of pulmonary exacerbations. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 17, 2014 Category: Science Source Type: news

Ataluren Phase 3 trial results in nonsense mutation cystic fibrosis
(University Hospitals Case Medical Center) PTC Therapeutics, Inc. today announced that the results of a Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis were published in Lancet Respiratory Medicine. The results demonstrated positive trends in both the primary endpoint, lung function as measured by relative change in percent predicted FEV1 (forced expiratory volume in one second) and in the secondary outcome measure, rate of pulmonary exacerbations. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 16, 2014 Category: Global & Universal Source Type: news

Management of cystic fibrosis
The pharmacological treatment of cystic fibrosis, together with implications for health economics, therapeutic monitoring and adherence, are discussed (Source: Pharmacy Europe)
Source: Pharmacy Europe - May 9, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news

Aradigm begins dosing in Phase III trial of pulmaquin to treat non-cystic fibrosis bronchiectasis
US-based pharmaceutical firm Aradigm has dosed first patient in the ORBIT-3 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) Phase III clinical trial of its proprietary formulation of inhaled ciprofloxacin (Pulmaquin) to treat non-cystic … (Source: Drug Development Technology)
Source: Drug Development Technology - May 2, 2014 Category: Pharmaceuticals Source Type: news

Man gets 11th hour lung transplant and goes on to marry love of his life
Dane Pollard, 34, from Manchester, was diagnosed with cystic fibrosis when he was 18 months old and believes he was close to death when he had his transplant. (Source: the Mail online | Health)
Source: the Mail online | Health - April 29, 2014 Category: Consumer Health News Source Type: news

Targeting the cause of Cystic Fibrosis
An NIHR-funded review looking at the effectiveness of a new drug at treating patients with Cystic Fibrosis has published its results in Health Technology Assessment.Cystic Fibrosis (CF) is a common disease that affects around 1 in every 2,500 babies born in the UK. It’s caused by a faulty gene and results in internal organs being... (Source: NIHR Evaluation, Trials and Studies News)
Source: NIHR Evaluation, Trials and Studies News - April 28, 2014 Category: American Health Source Type: news

Low-dose natural antimicrobial exacerbates chronic lung infection in cystic fibrosis
Respiratory failure caused by chronic lung infection with Pseudomonas aeruginosa bacteria is a common cause of death in patients with cystic fibrosis, a genetic disease that is common in individuals of European descent. A new study demonstrates that an antimicrobial peptide produced by human immune cells can promote mutations in the bacterium that make it more lethal. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 24, 2014 Category: Science Source Type: news

FDA grants orphan drug status to Bayer's bronchiectasis medicine Ciprofloxacin DPI
The US Food and Drug Administration (FDA) has granted orphan drug designation for Bayer HealthCare's investigational Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) to treat patients with non-cystic fibrosis bronchiectasis (NCFB). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 24, 2014 Category: Pharmaceuticals Source Type: news